This article was originally published on ETFTrends.com.
A targeted biotechnology ETF strategy jumped Friday after Editas Medicine (NasdaqGS: EDIT) announced fourth quarter results, revealing its latest progress toward the commercialization of its EDIT-101 drug candidate and its expansion into other novel CRISPR developments. The ARK Genomic Revolution Multi-Sector Fund (NYSEArca: ARKG), which provides exposure to CRISPR, gene editing, therapeutics, agricultural biology and […]
Continue Reading Below